Clinigen Group Acquires Oncology Support Therapy SAVENE® (Dexrazoxane) From SpePharm

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC